Vyome Holdings, Inc. (HIND)
NASDAQ: HIND · Real-Time Price · USD
1.580
0.00 (0.00%)
Nov 16, 2026, 9:34 AM EST - Market open
Vyome Holdings Revenue
Vyome Holdings had revenue of $58.00K in the quarter ending September 30, 2026, with 67.49% growth. This brings the company's total for the last twelve months to $153.10K, down -55.57% year-over-year. In the year 2025, Vyome Holdings had annual revenue of $319.71K with 24.43% growth. That makes Vyome Holdings the 45,756th largest company in the world by revenue and 6,706th in the United States.
Revenue (ttm)
$153.10K
Revenue Growth
-55.57%
P/S Ratio
72.43
Revenue / Employee
$10,935
Employees
14
Market Cap
11.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 319.71K | 62.77K | 24.43% |
| Dec 31, 2024 | 256.94K | -159.00K | -38.23% |
| Dec 31, 2023 | 415.94K | 33.08K | 8.64% |
| Dec 31, 2022 | 382.87K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
HIND News
- Just now - Vyome Holdings Quarterly report: Q3 2026 - Filings
- 59 minutes ago - Vyome reports Q3 EPS (13c) vs ($3.06) last year - TheFly
- 21 days ago - Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School - Business Wire
- 27 days ago - Vyome Holdings Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 6 weeks ago - Vyome receives USPTO Notice of Allowance for U.S. patent covering VT-1908 - TheFly
- 6 weeks ago - Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market - Business Wire
- 2 months ago - Vyome appoints Leonard as Chief Financial Officer - TheFly
- 2 months ago - Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer - Business Wire